{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:23:49Z","timestamp":1768555429925,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00467-018-4173-2","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T03:59:10Z","timestamp":1547006350000},"page":"917-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A breakthrough in readthrough? Could geneticin lead the way to effective treatment for cystinosis nonsense mutations?"],"prefix":"10.1007","volume":"34","author":[{"given":"Julian","family":"Midgley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"key":"4173_CR1","doi-asserted-by":"publisher","unstructured":"Brasell EJ, Chu L, El Kares R, Seo JH, Loesch R, Iglesias DM, Goodyer P (2018) The aminoglycoside geneticin permits translational readthrough of the CTNS W138X nonsense mutation in fibroblasts from patients with nephropathic cystinosis. Pediatr Nephrol. \n                    https:\/\/doi.org\/10.1007\/s00467-018-4094-0","DOI":"10.1007\/s00467-018-4094-0"},{"key":"4173_CR2","doi-asserted-by":"publisher","first-page":"F905","DOI":"10.1152\/ajprenal.00318.2010","volume":"299","author":"MJ Wilmer","year":"2010","unstructured":"Wilmer MJ, Emma F, Levtchenko EN (2010) The pathogenesis of cystinosis: mechanisms beyond cystine accumulation. Am J Physiol Ren Physiol 299:F905\u2013F916","journal-title":"Am J Physiol Ren Physiol"},{"key":"4173_CR3","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s10545-010-9203-6","volume":"33","author":"P Sansanwal","year":"2010","unstructured":"Sansanwal P, Li L, Hsieh SC, Sarwal MM (2010) Insights into novel cellular injury mechanisms by gene expression profiling in nephropathic cystinosis. J Inherit Metab Dis 33:775\u2013786","journal-title":"J Inherit Metab Dis"},{"key":"4173_CR4","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/10409238.2012.694846","volume":"47","author":"KM Keeling","year":"2012","unstructured":"Keeling KM, Wang D, Conard SE, Bedwell DM (2012) Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol 47:444\u2013463","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"4173_CR5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1172\/JCI7866","volume":"104","author":"ER Barton-Davis","year":"1999","unstructured":"Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104:375\u2013381","journal-title":"J Clin Invest"},{"key":"4173_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.tig.2008.08.010","volume":"24","author":"L Linde","year":"2008","unstructured":"Linde L, Kerem B (2008) Introducing sense into nonsense in treatments of human genetic diseases. Trends Genet 24:552\u2013563","journal-title":"Trends Genet"},{"key":"4173_CR7","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.jid.2017.05.011","volume":"137","author":"VS Atanasova","year":"2017","unstructured":"Atanasova VS, Jiang Q, Prisco M, Gruber C, Pinon Hofbauer J, Chen M, Has C, Bruckner-Tuderman L, McGrath JA, Uitto J, South AP (2017) Amlexanox enhances premature termination codon read-through in COL7A1 and expression of full length type VII collagen: potential therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 137:1842\u20131849","journal-title":"J Invest Dermatol"},{"key":"4173_CR8","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1080\/14656566.2017.1359255","volume":"18","author":"N Zainal Abidin","year":"2017","unstructured":"Zainal Abidin N, Haq IJ, Gardner AI, Brodlie M (2017) Ataluren in cystic fibrosis: development, clinical studies and where are we now? Expert Opin Pharmacother 18:1363\u20131371","journal-title":"Expert Opin Pharmacother"},{"key":"4173_CR9","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, Heydemann P, Kaminska A, Kirschner J, Muntoni F, Osorio AN, Schara U, Sejersen T, Shieh PB, Sweeney HL, Topaloglu H, Tulinius M, Vilchez JJ, Voit T, Wong B, Elfring G, Kroger H, Luo X, McIntosh J, Ong T, Riebling P, Souza M, Spiegel RJ, Peltz SW, Mercuri E, Clinical Evaluator Training Group, ACT DMD Study Group (2017) Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:1489\u20131498","journal-title":"Lancet"},{"key":"4173_CR10","first-page":"S75","volume":"1","author":"JG Thoene","year":"2000","unstructured":"Thoene JG, Lemons R (2000) Correction of cystinotic phenotype in cultured cells by an aminoglycoside. Mol Ther 1:S75","journal-title":"Mol Ther"},{"key":"4173_CR11","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1006\/mgme.2001.3272","volume":"75","author":"A Helip-Wooley","year":"2002","unstructured":"Helip-Wooley A, Park MA, Lemons RM, Thoene JG (2002) Expression of CTNS alleles: subcellular localization and aminoglycoside correction in vitro. Mol Genet Metab 75:128\u2013133","journal-title":"Mol Genet Metab"},{"key":"4173_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.5483\/BMBRep.2013.46.1.002","volume":"46","author":"J Hwang","year":"2013","unstructured":"Hwang J, Kim YK (2013) When a ribosome encounters a premature termination codon. BMB Rep 46:9\u201316","journal-title":"BMB Rep"},{"key":"4173_CR13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1017\/S1355838200000716","volume":"6","author":"M Manuvakhova","year":"2000","unstructured":"Manuvakhova M, Keeling K, Bedwell DM (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044\u20131055","journal-title":"RNA"},{"key":"4173_CR14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/sj.gt.3302211","volume":"11","author":"L Bidou","year":"2004","unstructured":"Bidou L, Hatin I, Perez N, Allamand V, Panthier JJ, Rousset JP (2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 11:619\u2013627","journal-title":"Gene Ther"},{"key":"4173_CR15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1128\/MMBR.53.3.273-298.1989","volume":"53","author":"J Parker","year":"1989","unstructured":"Parker J (1989) Errors and alternatives in reading the universal genetic code. Microbiol Rev 53:273\u2013298","journal-title":"Microbiol Rev"},{"key":"4173_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2199-2-3","volume":"2","author":"M Cassan","year":"2001","unstructured":"Cassan M, Rousset JP (2001) UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals. BMC Mol Biol 2:3","journal-title":"BMC Mol Biol"},{"key":"4173_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature05756","volume":"447","author":"EM Welch","year":"2007","unstructured":"Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, Paushkin S, Patel M, Trotta CR, Hwang S, Wilde RG, Karp G, Takasugi J, Chen G, Jones S, Ren H, Moon YC, Corson D, Turpoff AA, Campbell JA, Conn MM, Khan A, Almstead NG, Hedrick J, Mollin A, Risher N, Weetall M, Yeh S, Branstrom AA, Colacino JM, Babiak J, Ju WD, Hirawat S, Northcutt VJ, Miller LL, Spatrick P, He F, Kawana M, Feng H, Jacobson A, Peltz SW, Sweeney HL (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87\u201391","journal-title":"Nature"},{"key":"4173_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s10020-018-0024-7","volume":"24","author":"M Dabrowski","year":"2018","unstructured":"Dabrowski M, Bukowy-Bieryllo Z, Zietkiewicz E (2018) Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons. Mol Med 24:25","journal-title":"Mol Med"},{"key":"4173_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/BF00710050","volume":"18","author":"JG Thoene","year":"1995","unstructured":"Thoene JG (1995) Cystinosis. J Inherit Metab Dis 18:380\u2013386","journal-title":"J Inherit Metab Dis"},{"key":"4173_CR20","first-page":"CD012040","volume":"1","author":"AA Aslam","year":"2017","unstructured":"Aslam AA, Higgins C, Sinha IP, Southern KW (2017) Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis. Cochrane Database Syst Rev 1:CD012040","journal-title":"Cochrane Database Syst Rev"},{"key":"4173_CR21","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","volume":"18","author":"I Nudelman","year":"2010","unstructured":"Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T (2010) Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18:3735\u20133746","journal-title":"Bioorg Med Chem"},{"key":"4173_CR22","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1084\/jem.20081940","volume":"206","author":"L Du","year":"2009","unstructured":"Du L, Damoiseaux R, Nahas S, Gao K, Hu H, Pollard JM, Goldstine J, Jung ME, Henning SM, Bertoni C, Gatti RA (2009) Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 206:2285\u20132297","journal-title":"J Exp Med"},{"key":"4173_CR23","doi-asserted-by":"publisher","first-page":"42583","DOI":"10.1038\/srep42583","volume":"7","author":"MA Elmonem","year":"2017","unstructured":"Elmonem MA, Khalil R, Khodaparast L, Khodaparast L, Arcolino FO, Morgan J, Pastore A, Tylzanowski P, Ny A, Lowe M, de Witte PA, Baelde HJ, van den Heuvel LP, Levtchenko E (2017) Cystinosis (ctns) zebrafish mutant shows pronephric glomerular and tubular dysfunction. Sci Rep 7:42583","journal-title":"Sci Rep"},{"key":"4173_CR24","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1164\/rccm.201601-0154OC","volume":"194","author":"V Mutyam","year":"2016","unstructured":"Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, Bedwell DM, Rowe SM (2016) Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations. Am J Respir Crit Care Med 194:1092\u20131103. \n                    https:\/\/doi.org\/10.1164\/rccm.201601-0154OC","journal-title":"Am J Respir Crit Care Med"},{"key":"4173_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/ndt\/gft270","volume":"29","author":"S Cherqui","year":"2014","unstructured":"Cherqui S (2014) Is genetic rescue of cystinosis an achievable treatment goal? Nephrol Dial Transplant 29:522\u2013528","journal-title":"Nephrol Dial Transplant"},{"key":"4173_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1097\/MOP.0000000000000462","volume":"29","author":"KR Veys","year":"2017","unstructured":"Veys KR, Elmonem MA, Arcolino FO, van den Heuvel L, Levtchenko E (2017) Nephropathic cystinosis: an update. Curr Opin Pediatr 29:168\u2013178","journal-title":"Curr Opin Pediatr"},{"key":"4173_CR27","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s13311-015-0368-4","volume":"12","author":"L Matalonga","year":"2015","unstructured":"Matalonga L, Arias A, Tort F, Ferrer-Cortes X, Garcia-Villoria J, Coll MJ, Gort L, Ribes A (2015) Effect of readthrough treatment in fibroblasts of patients affected by lysosomal diseases caused by premature termination codons. Neurotherapeutics 12:874\u2013886","journal-title":"Neurotherapeutics"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4173-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T09:25:42Z","timestamp":1585905942000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4173"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4173-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The author declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}